ArticleBMJ case reports2015
Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.
Article in BMJ case reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review.PloS one · 2019Pooled it
- Antibiotic-Induced Genotoxicity: Molecular Mechanisms, Cytogenetic Damage, and Implications for Human Health.International journal of molecular sciences · 2026Review
- Depleted before the dose: the mitochondrial vulnerability threshold hypothesis for fluoroquinolone-associated multisystem toxicity.Frontiers in pharmacology · 2026Article
- Fluoroquinolone-Associated Disability: A Rodent Model Reveals Transient Neuropsychiatric and Persistent Gastrointestinal Effects of Low-Dose Ciprofloxacin.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Gelatin-Based Microspheres of Ciprofloxacin for Enhanced Lung Delivery and Biofilm Eradication inGels (Basel, Switzerland) · 2025Article
- Mitochondrial Impairment in Healthy Controls With Recent Headache and Multiple Symptoms.Cureus · 2025Article
- Article
- Susceptibility to radiation adverse effects in veterans with Gulf War illness and healthy civilians.Scientific reports · 2024Article
- Antibiotic-induced neuropsychiatric toxicity: epidemiology, mechanisms and management strategies - a narrative literature review.Drugs in context · 2024Review
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease.Frontiers in immunology · 2024Review
- Mitochondrial impairment but not peripheral inflammation predicts greater Gulf War illness severity.Scientific reports · 2023Article
- Preparation of Co-Amorphous Levofloxacin Systems for Pulmonary Application.Pharmaceutics · 2023Article
- Head rebound test in the clinical neurological examination of veterinary patients: a case example and discussion of Stewart and Holmes' rebound phenomenon.Frontiers in veterinary science · 2023Article
- Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: aFrontiers in medicine · 2023Article
- Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy.Stem cell research & therapy · 2022Article
- Healthcare costs and mortality associated with serious fluoroquinolone-related adverse reactions.Pharmacology research & perspectives · 2022Article
- How Safe are Fluoroquinolones for Diabetic Patients? A Systematic Review of Dysglycemic and Neuropathic Effects of Fluoroquinolones.Therapeutics and clinical risk management · 2021Review
- Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR).EClinicalMedicine · 2021Article
- Mannose Conjugated Polymer TargetingACS infectious diseases · 2020Article
- Potential adverse effects of ciprofloxacin and tetracycline on ARPE-19 cell lines.BMJ open ophthalmology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a case series of four previously healthy, employed adults without significant prior medical history in each of whom symptoms developed while on fluoroquinolones (FQs), with progression that continued following discontinuation evolving to a severe, disabling multisymptom profile variably involving tendinopathy, muscle weakness, peripheral neuropathy, autonomic dysfunction, sleep disorder, cognitive dysfunction and psychiatric disturbance. Physicians and patients should be alert to the potential for FQ-induced severe disabling multisymptom pathology that may persist and progress following FQ use. Known induction by FQs of delayed mitochondrial toxicity provides a compatible mechanism, with symptom profiles (and documented mechanisms of FQ toxicity) compatible with the hypothesis of an exposure-induced mitochondrial neurogastrointestinal encephalomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.